LEO Pharma Announces Publication of Adbry™ (tralokinumab-ldrm) Efficacy Data in Moderate-to-Severe Atopic Dermatitis in American Journal of Clinical Dermatology  https://t.co/G34GJENx9G  https://t.co/8adKtj0BRy